Gilead Sciences (GILD) Bullish Stance Reiterated at Nomura as HIV Succession Plan Coming into Focus
Tweet Send to a Friend
Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating and $141 price target on Gilead Sciences (NASDAQ: GILD) as ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
